


Author's Accepted Manuscript

Immunotherapy for Prostate Cancer: Why Now?

Max Kates, Charles G. Drake



PII: S2352-0779(16)30208-4
DOI: [10.1016/j.urpr.2016.07.010](https://doi.org/10.1016/j.urpr.2016.07.010)
Reference: URPR 226

To appear in: *Urology Practice*
Accepted Date: 26 July 2016

Please cite this article as: Kates M, Drake CG, Immunotherapy for Prostate Cancer: Why Now?, *Urology Practice* (2016), doi: 10.1016/j.urpr.2016.07.010.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

All press releases and the articles they feature are under strict embargo until uncorrected proof of the article becomes available online. We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date.

Immunotherapy for Prostate Cancer: Why Now?

Max Kates¹, Charles G Drake^{1,2}

¹James Buchanan Brady Urological Institute, Johns Hopkins, Baltimore, MD, USA

²Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA

Correspondence:

Max Kates, M.D.

James Buchanan Brady Urological Institute

Johns Hopkins Medical Institutions

1800 Orleans Street

Marburg 134

Baltimore, MD 21287

E-mail: mkates@jhmi.edu

Manuscript Pages:

Submission Type: Review article

Word Count: 2340

Download English Version:

<https://daneshyari.com/en/article/8830333>

Download Persian Version:

<https://daneshyari.com/article/8830333>

[Daneshyari.com](https://daneshyari.com)